Antigen Binding Proteins Neutralize PCSK9 to Preserve LDLR
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective solutions to neutralize the LDL-lowering effect of PCSK9 on LDLR, which contributes to elevated serum cholesterol levels, as existing methods fail to adequately inhibit PCSK9's interaction with LDLR.
Innovation Solution
Development of antigen binding proteins that specifically bind to PCSK9, reducing its interaction with LDLR by targeting specific epitopes, thereby increasing LDLR availability and decreasing serum cholesterol levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PCSK9 is present to regulate LDLR levels, then plasma cholesterol control is maintained, but LDLR levels decrease and serum cholesterol increases
Solution Approach 1:
The patent introduces an antibody as an intermediary substance that binds to PCSK9, preventing PCSK9 from interacting with LDLR. This mediator blocks the harmful interaction while allowing PCSK9 to continue its natural regulation function, thereby preserving LDLR levels and reducing serum cholesterol.
2Reliability
If PCSK9 interacts with LDLR to lower LDLR levels, then PCSK9's natural function is fulfilled, but therapeutic effect for hypercholesterolemia is reduced
Solution Approach 1:
The patent extracts or removes PCSK9 from its harmful interaction with LDLR by introducing an antibody that specifically binds to PCSK9. This sequesters PCSK9 in an antibody-PCSK9 complex, preventing it from interacting with LDLR and thereby eliminating the harmful effect while preserving PCSK9's natural function.
3Quantity of substance
If existing methods are used to inhibit PCSK9, then some inhibition is achieved, but adequate neutralization of PCSK9's LDLR-lowering effect is not achieved
Solution Approach 1:
The patent employs parameter changes by optimizing the antibody's binding affinity and specificity for PCSK9. By carefully selecting and engineering antibodies with appropriate binding characteristics, the patent achieves adequate neutralization of PCSK9's LDLR-lowering effect, transforming insufficient inhibition into effective therapy.
Data Source
Figure 1A
Figure 1B1
Figure 1B2
AI summary
Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.